Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. develops biopharmaceutical products using a proprietary technology platform for effective oral drug delivery. News about LPCN centers on clinical development of LPCN 1154, an oral brexanolone product candidate for postpartum depression, including trial progress, safety reviews and reported efficacy results.
Company updates also cover TLANDO, Lipocine’s oral testosterone replacement therapy, and related license, supply and distribution arrangements in multiple territories. Recurring financial news includes research and development spending, royalty revenue from TLANDO sales, pipeline prioritization and corporate presentations tied to the company’s oral-delivery programs.
Lipocine Inc. (NASDAQ: LPCN) announced a dividend distribution of one one-thousandth of a share of newly designated Series B Preferred Stock for each outstanding share of common stock, effective March 24, 2023. This preferred stock will grant significant voting rights on matters including a potential reverse stock split. Uncertificated and non-transferable, the Series B Preferred Stock can be redeemed if not represented at the stockholder meeting. The company aims to maintain its capitalization structure post-distribution. Further details will follow in a Form 8-K filing with the SEC.
Lipocine Inc. (NASDAQ: LPCN) announced its management team will present at the Biotech Showcase and participate in the LifeSci Partners Corporate Access Event from January 9-11, 2023, in San Francisco. The presentation is scheduled for January 11 at 9 AM PT at the Hilton Hotel Union Square. Investors can attend in person or via webcast. Lipocine focuses on CNS disorder treatments and is exploring partnerships for various product candidates, including LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy.
Lipocine Inc. (NASDAQ: LPCN) has completed enrollment in its Phase 2 proof-of-concept study for LPCN 1148, targeting decompensated cirrhosis, with top-line results expected in mid-2023. The study focuses on the effects of LPCN 1148 on improving muscle function and outcomes in cirrhotic patients. This condition affects over 500,000 Americans annually, with high mortality rates. The ongoing research is vital as it addresses a significant unmet medical need, and the company plans to explore potential partnerships for LPCN 1148.
Lipocine Inc. (NASDAQ: LPCN) announced its Q3 and nine-month financial results for 2022, reporting a net loss of $2.4 million ($0.03 per diluted share) for Q3, an improvement from $3.1 million ($0.04 per diluted share) in Q3 2021. Revenues remained flat at $0, down from $55,000 in the previous year. R&D expenses decreased to $2.1 million, while G&A expenses fell to $0.8 million. As of September 30, 2022, cash reserves stood at $34.3 million, down from $46.6 million at year-end 2021. The company is shifting focus to CNS disorders, notably postpartum depression treatment LPCN 1154.
Lipocine Inc. (NASDAQ: LPCN) has announced key leadership appointments, with George Nomikos, M.D., Ph.D. appointed Chief Medical Officer and Spyros Papapetropoulos, M.D., Ph.D. as Lead Director and Chairman of the Board. The FDA has agreed to Lipocine's plan to establish the efficacy of LPCN 1154 for postpartum depression via a pivotal pharmacokinetic study. A pilot study has started, with results expected in the first half of 2023. LPCN 1154 aims to be the fastest acting oral treatment for postpartum depression, enhancing Lipocine's focus on CNS disorders.
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 3:30 p.m. EST. The conference will be held virtually, and interested investors can arrange 1x1 meetings with representatives. Lipocine focuses on developing oral delivery products for CNS disorders using its proprietary Lip'ral platform. Key clinical candidates include LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. Lipocine also explores partnerships for several other treatment candidates.
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Cantor Neurology & Psychiatric Conference taking place on October 6-7, 2022 in San Francisco. The conference will be held at the Ritz Carlton Hotel, where investors can arrange 1x1 meetings. Lipocine focuses on developing products for CNS disorders through its proprietary Lip'ral platform, with candidates in development like LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. The company aims to provide effective oral delivery options for significant medical needs.
Lipocine Inc. (NASDAQ: LPCN) announced a strategic focus on developing treatments for Central Nervous System (CNS) disorders using its proprietary Lip'ral oral drug delivery technology. The initial target is LPCN 1154, an oral neuroactive steroid for postpartum depression (PPD). The FDA has agreed on a pivotal pharmacokinetic study to establish efficacy via a 505(b)(2) NDA filing. Lipocine plans to explore partnerships to advance non-core products, ensuring efficient resource management. As of June 30, 2022, the company had $37.4 million in cash, sufficient for operations until at least September 30, 2023.
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Ladenburg Thalmann 2022 Healthcare Conference, scheduled for September 29, 2022, in New York. The presentation will take place from 3:00 to 3:25 p.m. EST at the Sofitel Hotel. The company focuses on enhancing therapeutics through its Lip'ral platform, developing oral delivery options for conditions like postpartum depression and liver cirrhosis. Interested investors can arrange 1x1 meetings through their Ladenburg Thalmann representatives.
Lipocine has received FDA agreement to establish efficacy for LPCN 1154, an oral formulation for postpartum depression (PPD). The drug is based on brexanolone, with exposure similar to that seen in pregnant women. A pivotal pharmacokinetic (PK) bridge study is set for 4Q 2022, with results expected in 1Q 2023. This could lead to the first oral treatment option for PPD, addressing significant market needs. Lipocine's technology platform aims to create accessible therapies, potentially revolutionizing PPD treatment.